# CheckMate 7FL (NCT04109066)

> Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04109066
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Breast Cancer
- Interventions: nivolumab; paclitaxel (PTX); nivolumab placebo; anthracycline; cyclophosphamide; Endocrine Therapy; Surgery
- Enrollment: 521
- Primary outcome: Pathological Complete Response (pCR) Rate

## Commentary we found

- X threads: 37
- Podcasts: 29
- YouTube: 27

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-7fl-nct04109066

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04109066", "email": "<work email>"}; the inbox owner confirms by the emailed link.